Real-world study explores safety of pegcetacoplan in geographic atrophy
Click Here to Manage Email Alerts
The first analysis of real-world outcomes in patients with neovascular age-related macular degeneration treated with pegcetacoplan for geographic atrophy demonstrated similar safety seen in clinical trials, according to a study.
At the American Society of Retina Specialists meeting, Janani Singaravelu, MD, presented a retrospective, observational cohort study that included 1,451 eyes with geographic atrophy, 991 (68.2%) with non-neovascular AMD and 460 (31.8%) with neovascular AMD.
The mean follow-up time was 7.5 months after the initial pegcetacoplan injection. Approximately 84% of patients had a follow-up time of more than 6 months. The majority of patients underwent treatment at intervals between 25 and 68 days.
In the group of eyes with wet AMD, the mean number of anti-VEGF injections in the year before the first pegcetacoplan injection was 5.7. After the first pegcetacoplan injection, the mean number of anti-VEGF injection was similar at 4.5. The mean treatment interval was also similar before and after pegcetacoplan, 9.16 weeks and 8.8 weeks, respectively.
There were 76 cases of ocular hypertension, two cases of posterior vitreous detachment, three cases of retinal detachment and five cases of intraocular inflammation. Among the cases of intraocular inflammation, three were attributed to anterior uveitis, one to non-occlusive vasculitis and one to occlusive vasculitis, Singaravelu said.
“Rate of overall [intraocular inflammation] was 0.1% per injection, which was slightly lower than what was seen in GALE at 0.25% per injection,” she said.
Additionally, 76 cases on new-onset neovascular AMD were identified. Singaravelu said the 5.2% conversion rate was similar to the 7.1% rate seen in the GALE study.
“This is the first description of outcomes in patients with neovascular AMD treated with pegcetacoplan,” Singaravelu said. “We show that the mean number in treatment interval of anti-VEGF injections is comparable before and after pegcetacoplan.”
Collapse
Singaravelu J, et al. Real-world clinical usage and safety profile of intravitreal pegcetacoplan in patients with geographic atrophy. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Click Here to Manage Email Alerts